low grade glioma
Information
- Disease name
- low grade glioma
- Disease ID
- DOID:0080829
- Description
- "A cell type benign neoplasm that has_material_basis_in glial cells (astrocytes, oligodendrocytes or ependymocytes)." [url:http\://www.danafarberbostonchildrens.org/conditions/brain-tumor/low-grade-glioma.aspx, url:https\://www.cancer.gov/publications/dictionaries/cancer-terms/def/glioma, url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361022/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01089101 | Active, not recruiting | Phase 1/Phase 2 | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | April 19, 2010 | December 1, 2025 |
| NCT01288235 | Active, not recruiting | Phase 2 | Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation | February 2011 | September 2025 |
| NCT01358058 | Active, not recruiting | N/A | Proton Radiation Therapy for Gliomas | May 2011 | November 2025 |
| NCT02840409 | Active, not recruiting | Phase 2 | Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) | August 1, 2016 | August 2026 |
| NCT03213665 | Active, not recruiting | Phase 2 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | November 13, 2017 | September 22, 2024 |
| NCT03233204 | Active, not recruiting | Phase 2 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | September 14, 2017 | September 22, 2024 |
| NCT03244995 | Active, not recruiting | N/A | Mind-Body Intervention in Glioma Couples | August 6, 2017 | October 31, 2024 |
| NCT04553757 | Active, not recruiting | Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma | July 8, 2020 | December 30, 2025 | |
| NCT04044937 | Completed | Phase 2 | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms | October 29, 2018 | March 31, 2024 |
| NCT02286531 | Completed | N/A | Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma | June 2010 | December 2014 |
| NCT02186262 | Completed | Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas | March 2014 | December 2017 | |
| NCT02607397 | Completed | ROCOCO - Low Grade Glioma - Planning Study | May 2015 | March 2017 | |
| NCT06132685 | Not yet recruiting | Phase 2 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | July 1, 2024 | July 30, 2028 |
| NCT03871257 | Recruiting | Phase 3 | A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma | January 15, 2020 | May 1, 2027 |
| NCT03952598 | Recruiting | N/A | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy | October 16, 2019 | December 31, 2025 |
| NCT03749187 | Recruiting | Phase 1 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas | April 3, 2019 | July 30, 2029 |
| NCT04166409 | Recruiting | Phase 3 | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | January 31, 2020 | December 31, 2026 |
| NCT05964569 | Recruiting | Phase 2 | Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma | November 11, 2023 | November 11, 2028 |
| NCT03718767 | Recruiting | Phase 2 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | March 27, 2019 | February 27, 2026 |
| NCT02358187 | Recruiting | Phase 2 | A Vaccine Trial for Low Grade Gliomas | January 2015 | August 31, 2025 |
| NCT01452854 | Terminated | Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide | October 2011 | November 2013 | |
| NCT02023905 | Terminated | Phase 2 | Everolimus With and Without Temozolomide in Adult Low Grade Glioma | March 19, 2014 | September 30, 2021 |
| NCT01281982 | Terminated | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | January 13, 2011 | September 24, 2012 | |
| NCT02455245 | Unknown status | Phase 3 | A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma | March 2015 | April 2021 |
- Disase is a (Disease Ontology)
- DOID:0060084
- Cross Reference ID (Disease Ontology)
- NCI:C132067
- Exact Synonym (Disease Ontology)
- benign glioma